ATA 188
Alternative Names: Allogeneic ATA 188; Allogeneic EBV-directed T-cell therapy; ATA-188; EBV-CTLs; EBV-targeted T-cell; Epstein-Barr Virus-directed cytotoxic T lymphocytes; Off-the-shelf ATA188Latest Information Update: 05 Apr 2024
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Atara Biotherapeutics
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Multiple sclerosis
Highest Development Phases
- Phase II Multiple sclerosis
Most Recent Events
- 04 Apr 2024 ATA 188 is available for licensing as of 05 Apr 2024. https://www.sec.gov/ix?doc=/Archives/edgar/data/1604464/000095017024037644/atra-20231231.htm
- 04 Apr 2024 Atara Biotherapeutics paused the development for Multiple sclerosis (Atara Biotherapeutics SEC 2024)
- 17 Jan 2024 Atara Biotherapeutics terminates a phase I/II EMBOLD trial in Multiple sclerosis (Treatment-experienced) in USA, Australia, and Canada (IV), due to the primary endpoint not being achieved (NCT03283826)